^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pegylated irinotecan (SSS22)

    i
    Other names: SSS22, JK-1201I, injectable PEG-irinotecan
    Associations

    News

    Trials
    Company:
    3SBio
    Drug class:
    DNA topoisomerase inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer (ChiCTR2400090371)
    P3, N=394, Not yet recruiting, Jilin Cancer Hospital; Jilin Cancer Hospital
    New P3 trial
    |
    topotecan • pegylated irinotecan (SSS22)
    3ms
    JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
    P2, N=25, Recruiting, JenKem Technology Co., Ltd.
    New P2 trial • Surgery
    |
    temozolomide • pegylated irinotecan (SSS22)
    3ms
    JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, JenKem Technology Co., Ltd.
    New P2 trial
    |
    pegylated irinotecan (SSS22)
    4ms
    JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=394, Not yet recruiting, JenKem Technology Co., Ltd.
    New P3 trial
    |
    topotecan • pegylated irinotecan (SSS22)
    over1year
    Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug. (PubMed, Acta Pharm Sin B)
    In summary, PEG-[Irinotecan] displays superior pharmacokinetic characteristics and antitumor activity with lower toxicity than irinotecan. This supports the view that PEG-[Irinotecan] is a superior anticancer drug to irinotecan and it has entered the phase II trial stage.
    PK/PD data • Journal
    |
    irinotecan • Onzeald (etirinotecan pegol) • pegylated irinotecan (SSS22)